11 results about "Placental tissue" patented technology

The present application relates to the technical field of medical data fusion processing, and discloses a method and system for predicting adverse pregnancy outcomes of preeclampsia by fusing placental microenvironment image features and serum biomarkers, wherein the method comprises: obtaining digital whole field image of placental tissue section and serum biomarker detection data at the same period; constructing a multi-modal sample data set; extracting multi-scale structure features of placental microenvironment; constructing serum biomarker discriminant features; dynamically fusing placental image features and serum marker features; constructing a prediction model for adverse pregnancy outcomes of preeclampsia and outputting a prediction probability. Compared with the prior art which only relies on single image information or single serum biomarker for risk assessment, it is difficult to realize stable prediction of the coordinated changes of placental microenvironment abnormalities and biochemical abnormalities. Due to the multi-scale image structure analysis, the model generalization ability for predicting adverse pregnancy outcomes of preeclampsia is improved.

This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.

Methods for isolating a population of cells from tissue are disclosed herein. In particular, the present disclosure provides methods for isolating cytotrophoblasts from placental tissue. The methods include isolating a population of cells with the use of a laboratory apparatus that is coated with a lubricant, such as petroleum jelly. The methods described herein achieve consistent in vitro isolation of purified cells.

The invention is directed to a composition of soluble placental ECM in storage solution and the methods of manufacture related thereto. The solubilized placental ECM solution is manufactured through a process of partitioning placental ECM from the placental tissue in a high acidic pH environment and performing an ultrafiltration step and diafiltration step through a tangential flow filtration system to increase the pH. The soluble placental ECM retains the native characteristics of placental ECM components and includes collagens (types I, III, V, VI, IX, and X), elastin, laminin, and fibronectin.

This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.

The application discloses a kind of construction methods of mouse placenta targeted gene interference model and its application.The method comprises the following steps: first, pregnant mouse is anaesthetized and abdominal operation is carried out, and the uterus containing placenta is exposed;Then, the adeno-associated virus carrying gene interference element is directly injected into target placental tissue;Finally, the wound is sutured to complete model construction.The present application overcomes the problem of low virus delivery efficiency caused by maternal-fetal barrier by intraoperative direct site injection, and realizes the efficient and specific gene interference of placental tissue.The model constructed is targeted and precise, has high interference efficiency and low off-target effect, and provides an effective tool for studying placental gene function and pregnancy-related diseases.

A tissue storage solution includes hypothermic storage compositions and methods. The hypothermic storage composition includes media containing Dulbecco's modified Eagle's medium (DMEM) and albumin. A method of hypothermically storing tissue includes storing such tissue in a storage medium including DMEM and albumin. A method for wound or defect treatment includes applying tissue, stored in a hypothermic storage medium containing DMEM and albumin, to the site of such wound or defect.

The application provides application of a YTHDC1 inhibitor in preparation of a medicine for preventing and treating premature birth, and the medicine takes YTHDC1 gene as a target for placental trophoblasts. The application is based on the fact that the expression level of human YTHDC1 gene in premature placental tissue is significantly higher than that in full-term placenta, a stable overexpression cell strain is constructed aiming at human YTHDC1 gene, and specific siRNA is designed to specifically increase or reduce YTHDC1 expression in human placental trophoblasts, which can correspondingly promote or inhibit the proliferation, apoptosis, migration and invasion ability of the cells. Meanwhile, by injecting in vivo biological preparations interfering with the expression of YTHDC1 gene in an animal model, the expression of YTHDC1 at the placental site can be reduced, the delivery time is prolonged, and the purpose of delaying the occurrence of premature birth is achieved. The application provides a possibility for the development of a clinical premature birth treatment medicine based on YTHDC1 gene, and has great application value and prospect.

The application provides a rat uterine perfusion model and a construction method and application thereof, and belongs to the technical field of animal models. The construction method comprises the following steps: ligating blood vessels at a left kidney of a dead pregnant rat, blood vessels at a bifurcation of the upper end of the left kidney, bifurcation of the upper side and both sides of the internal iliac artery and the internal iliac vein, the right kidney and the bifurcation of the abdominal aorta and the posterior vena cava, and then inserting a tube into the abdominal aorta and the posterior vena cava, and pumping perfusion liquid from the abdominal aorta to obtain the model. The model forms a reproductive artery-placenta-fetus-placenta-reproductive vein circulation, maximally guarantees placental activity, and retains complete placental tissue. The model is simple to prepare and easy to obtain, can more truly and accurately simulate the circulation process of maternal body temperature and complete nutrients in the placenta supplied to the fetus through the mother and the placenta in the whole permeability experiment, and thus more objectively studies the permeability of a compound in the placenta, and is more reliable than a human placental perfusion model.

Systems and methods for assessing a level of prenatal hypoxia or placenta maturity. The method comprises transmitting ultrasonic waves into an in-vivo placenta, receiving ultrasonic reflections from the placenta, converting the received ultrasonic reflections into electrical signals, computationally determining, from the electrical signals, at least one measure of placenta tissue properties relating to the acoustic interaction of the placenta tissue with the transmitted ultrasonic waves, and determining the level of prenatal hypoxia or placenta maturity based on the at least one measure of the placenta tissue properties.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.